Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

India’s BDR Pharmaceuticals attempt to launch generic version of remdesivir looks difficult, says GlobalData

Following the news that India-based BDR Pharmaceuticals has sought the Drug Controller General of India (DCGI)’s approval to manufacture and sell the generic version of remdesivir without entering into a licensing pact with Gilead Sciences; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “This endeavor is not new […]
Read more

Gilead’s remdesivir has potential to be stockpiled by US federal government’s National Strategic Stockpile for COVID-19

As Gilead Sciences’ remdesivir continues to steal the COVID-19 spotlight, the antiviral is likely to be considered for inclusion in the top-secret US Strategic National Stockpile (SNS) to ensure supply, according to reporting by Reynald Castañeda and Manasi Vaidya, Pharma Writers for the Investigative News team at GlobalData, a leading data and analytics company. Castañeda comments: […]
Read more

mRNA-based vaccine technology innovate approach to treating COVID-19

Messenger RNA (mRNA) based vaccine technology is emerging as one of the frontrunners among the technologies being evaluated to develop a vaccine for COVID-19, with eighteen candidates currently in development globally, according to GlobalData, a leading data and analytics company. Keshalini Sabaratnam, Pharma Analyst at GlobalData, comments: “RNA vaccines are an innovative approach as they […]
Read more

Novavax’ might trail behind Clover’s COVID-19 vaccine due to the latter’s adjuvant choice, while IMV’s vaccine does not have adjuvant boost, says GlobalData

Following the announcement that Novavax has agreed a $167m deal to acquire Praha Vaccines to aid its manufacturing capabilities for its Phase I COVID-19 vaccine candidate; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view: “Novavax may be at a disadvantage compared to Clover Biopharmaceuticals, which also has a protein COVID-19 […]
Read more

Rapid Growth in Global Development of Cancer Cellular Immunotherapies Highlighted by Latest Report from Cancer Research Institute and GlobalData

A new report, published in Nature Reviews Drug Discovery, reveals that the cellular immunotherapy landscape continues to expand, with 472 more cellular therapies in development now than one year ago Of all cellular therapies, preclinical and Phase 1 development of allogeneic (off-the-shelf) therapies increased the most from last year Natural killer cells are being investigated in […]
Read more

Pharmaceutical software development less disrupted by COVID-19

Pharmaceutical software development has been less impacted by the COVID-19 crisis as it facilitates remote working and already had group collaboration tools and software processes in place to facilitate this type of work, says GlobalData, a leading data and analytics company.  Johanna Swanson, Product Manager at GlobalData, comments: “Numerous Software development systems have adopted a more […]
Read more

Leronlimab shows promise as a treatment for COVID-19

CytoDyn’s Leronlimab is a promising candidate for the treatment of COVID-19 and is currently forecast by GlobalData to have global peak sales of $747m in 2026 – putting it in second place after remdesivir, according to the current GlobalData sales forecast for COVID-19. Leronlimab is behind remdesivir in GlobalData’s estimates as remdesivir has emergency use authorization, […]
Read more

COVID-19 pandemic could improve treatment access for opioid use disorder

As a result of the COVID-19 pandemic, the treatment access for opioid use disorder (OUD) may increase; Philippa Salter, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “Despite the availability of multiple effective treatment options for managing OUD, key opinion leaders interviewed by GlobalData highlighted that there are many barriers […]
Read more

Sunovian’s novel sublingual formulation will address major unmet need in highly competitive Parkinson’s treatment market

Following the recent news that Sunovion Pharmaceuticals has received Food and Drug Administration (FDA) approval for Kynmobi (apomorphine), a novel sublingual film for the acute treatment of OFF episodes in patients with Parkinson’s disease (PD); Sarah Elsayed, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the opportunities and challenges […]
Read more

Label update to encourage prescription of anti-diabetic drugs outside the SGLT-2 inhibitor class

Following the FDA’s safety review on sodium glucose-transporter-2 (SGLT-2) inhibitors, a label update was issued stating that patients undergoing any scheduled surgery should discontinue treatment up to 3-4 days in advance of surgery. This label update is expected to influence physician decisions, encouraging the prescription of anti-diabetic drugs outside the SGLT-2 inhibitor class, according to GlobalData, a […]
Read more

Patients treated for hospital delirium will increase due to COVID-19

An estimated 70–80% of ventilated patients will experience ICU delirium, which causes patients to enter a confused state and can lead to long-term cognitive impairments and memory deficits. GlobalData, therefore, expects to see an increase in the administration of pharmacological treatments for ICU delirium as the COVID-19 outbreak continues. Johanna Swanson, Product Manager at GlobalData comments: […]
Read more

Ibudilast clinical trial launched for ARDS in COVID-19

Yale University launched a clinical trial of ibudilast (MN-166) to assess it as a treatment for COVID-19 patients with acute respiratory distress syndrome (ARDS), a cause of death in COVID-19 patients. The drug has anti-inflammatory and neuroprotective effects and suppresses the production of pro-inflammatory cytokines. It has approval in Japan for the treatment of asthma, […]
Read more

Alexion’s Soliris and Ultomiris for COVID-19 may have cost issues

Alexion is investigating monoclonal antibody treatments Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) as potential therapeutics for COVID-19. While these drugs have established safety data, they both have prophylactic antibiotic administration requirements to prevent meningococcal disease during treatment. Johanna Swanson, Product Manager at GlobalData, comments: “Both of these drugs are expensive at $500,000 and $458,000 a year […]
Read more

COVID-19 is causing childhood vaccination rates to plummet, says GlobalData

The COVID-19 pandemic caused a decrease in childhood vaccinations as preventative care was disrupted by the pandemic. The lack of vaccination could lead to another public healthcare crisis as diseases kept in check by vaccinations could have an outbreak, says GlobalData, a leading data and analytics company’. Natasha Karim, MPH, Managing Epidemiologist at GlobalData, comments: […]
Read more

University of Oxford vaccine showed no signs of worsening COVID-19 symptoms

The University of Oxford has reported positive findings from preclinical animal studies of its potential COVID-19 vaccine ChAdOx1, which involved nine rhesus macaques. The vaccine is currently undergoing human trials as they were performed concurrently with animal testing in order to fast track vaccine development. Johanna Swanson, Product Manager at GlobalData, comments: “The University of Oxford’s […]
Read more
1 … 91 92 93 94 95 … 108